Literature DB >> 21113691

Present and future of FDG-PET/CT in ovarian cancer.

Kazuhiro Kitajima1, Koji Murakami, Setsu Sakamoto, Yasushi Kaji, Kazuro Sugimura.   

Abstract

Integrated FDG-PET/CT has been used successfully for the diagnosis, staging, restaging, therapy monitoring and prognostic prediction of ovarian cancer as well as various other malignant tumors. Compared with conventional PET/non-contrast CT images, combined PET/contrast-enhanced CT images with intravenous iodine contrast medium and sufficient radiation dose may contribute to a more accurate diagnosis with higher confidence. In the future, tracers other than FDG and integrated PET/MRI will be realized. We herein review the place and role of FDG-PET/CT in the management of ovarian cancer, discussing its usefulness and limitations in the imaging of these patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21113691     DOI： 10.1007/s12149-010-0449-8

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN： 0914-7187            Impact factor:   2.668


  9 in total

1.  F-18 FDG PET/CT findings of metastatic ovarian tumors from gastrointestinal tract origin.

Authors:  Hye Lim Park; Ie Ryung Yoo; Joo Hyun O; Eun Ji Han; Sung Hoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-03       Impact factor: 4.553

2.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

3.  68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT.

Authors:  Chunxia Qin; Fuqiang Shao; Yongkang Gai; Qingyao Liu; Weiwei Ruan; Fang Liu; Fan Hu; Xiaoli Lan
Journal:  J Nucl Med       Date:  2021-04-16       Impact factor: 11.082

Review 4.  Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed?

Authors:  Subapriya Suppiah; Wing Liong Chang; Hasyma Abu Hassan; Chalermrat Kaewput; Andi Anggeriana Andi Asri; Fathinul Fikri Ahmad Saad; Abdul Jalil Nordin; Sobhan Vinjamuri
Journal:  World J Nucl Med       Date:  2017 Jul-Sep

5.  Assessment of Lymph Node Involvement with PET-CT in Advanced Epithelial Ovarian Cancer. A FRANCOGYN Group Study.

Authors:  Antoine Tardieu; Lobna Ouldamer; François Margueritte; Lauranne Rossard; Aymeline Lacorre; Nicolas Bourdel; Guillaume Lades; Camille Sallée; Jacques Monteil; Tristan Gauthier
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

6.  18FDG, [18F]FLT, [18F]FAZA, and 11C-methionine are suitable tracers for the diagnosis and in vivo follow-up of the efficacy of chemotherapy by miniPET in both multidrug resistant and sensitive human gynecologic tumor xenografts.

Authors:  György Trencsényi; Teréz Márián; Imre Lajtos; Zoltán Krasznai; László Balkay; Miklós Emri; Pál Mikecz; Katalin Goda; Gábor Szalóki; István Juhász; Enikő Németh; Tünde Miklovicz; Gábor Szabó; Zoárd T Krasznai
Journal:  Biomed Res Int       Date:  2014-09-18       Impact factor: 3.411

7.  Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.

Authors:  Filip Bochner; Liat Fellus-Alyagor; Dafna Ketter; Ofra Golani; Inbal Biton; Michal Neeman
Journal:  Br J Cancer       Date:  2020-05-11       Impact factor: 7.640

Review 8.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

9.  The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment: A retrospective clinical study.

Authors:  Yuanyuan Jiang; Guozhu Hou; Fengyu Wu; Zhaohui Zhu; Wei Zhang; Wuying Cheng
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.